Early Access

Early Access

ADC Therapeutics and our partners are committed to confronting cancer with the full potential of its science, bringing unique, targeted therapies and hope to patients and their families. Medical Affairs delivers scientific data and knowledge of the highest scientific and ethical standards to the healthcare community and the patients we serve.

Please submit requests to our partner Sobi for patient access to loncastuximab tesirine (lonca) in countries outside of the United States, excluding Greater China, Singapore and Japan, via their portal at: Managed Access Programmes | Sobi